12/5
05:43 am
mirm
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) [Yahoo! Finance]
Medium
Report
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) [Yahoo! Finance]
12/2
04:26 pm
mirm
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
Low
Report
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Evercore 8th Annual Healthcare Conference Transcript [Seeking Alpha]
12/1
08:10 am
mirm
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
Medium
Report
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome
11/25
04:24 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences [Yahoo! Finance]
11/25
04:02 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
11/10
08:00 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/7
08:40 am
mirm
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting® [Yahoo! Finance]
Low
Report
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD's The Liver Meeting® [Yahoo! Finance]
11/7
08:10 am
mirm
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
Low
Report
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
11/5
10:03 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
11/5
08:07 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Citizens Jmp from $81.00 to $95.00. They now have a "market outperform" rating on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at Citizens Jmp from $81.00 to $95.00. They now have a "market outperform" rating on the stock.
11/5
08:04 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $95.00 price target on by analysts at JMP Securities.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) was given a new $95.00 price target on by analysts at JMP Securities.
11/5
07:19 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/5
07:19 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/4
04:01 pm
mirm
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Low
Report
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
11/3
04:05 pm
mirm
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Low
Report
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
10/28
04:02 pm
mirm
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
Low
Report
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
10/25
12:09 pm
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/16
09:06 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
10/10
07:45 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/26
06:55 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
9/24
09:10 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) is now covered by analysts at Cowen Inc. They set a "buy" rating on the stock.
9/24
08:09 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) is now covered by analysts at TD Cowen. They set a "buy" rating and a $95.00 price target on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) is now covered by analysts at TD Cowen. They set a "buy" rating and a $95.00 price target on the stock.
9/21
10:55 am
mirm
Loss-Making Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
Medium
Report
Loss-Making Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Expected To Breakeven In The Medium-Term [Yahoo! Finance]
9/12
08:03 am
mirm
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at JPMorgan Chase & Co. from $53.00 to $77.00. They now have an "overweight" rating on the stock.
Low
Report
Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by analysts at JPMorgan Chase & Co. from $53.00 to $77.00. They now have an "overweight" rating on the stock.
9/10
06:45 pm
mirm
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)